Nomad Power Solutions (NMAD) Non Operating Interest Expenses (2021 - 2026)
Nomad Power Solutions (NMAD) posted Non Operating Interest Expenses of $851.0 for Q2 2026, down 77.34% on a QoQ basis from $3756.0 in Q4 2025, and down 52.98% year-over-year from $1810.0 in Q2 2025.
Analysis
Nomad Power Solutions (NMAD) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends
Nomad Power Solutions has reported Non Operating Interest Expenses for 6 years, with the latest figure at $851.0 in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses fell 52.98% year-over-year to $851.0 in Q2 2026; TTM through Jun 2026 was $6874.0, a 34.07% decrease from a year earlier, with the FY2025 full-year figure at $9158.0, down 45.56% from the prior year.
- Non Operating Interest Expenses was $851.0 for Q2 2026 at Nomad Power Solutions, down from $3756.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $10145.0 in Q4 2023, with the low at $279.0 in Q3 2023.
- Average Non Operating Interest Expenses over 5 years is $3055.2, with a median of $2494.0 recorded in 2022.
- The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses tumbled 86.83% in 2023, then jumped 275.99% in 2024.
- Over 5 years, Non Operating Interest Expenses stood at $3635.0 in 2022, then surged by 179.09% to $10145.0 in 2023, then sank by 56.31% to $4432.0 in 2024, then decreased by 15.25% to $3756.0 in 2025, then sank by 77.34% to $851.0 in 2026.
- The last three Non Operating Interest Expenses figures came in at $851.0 (Q2 2026), $3756.0 (Q4 2025), and $457.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Nomad Power Solutions | 49.59 Mn | 49.59 Mn | - | 851.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 851.00 |
| Dec 31, 2025 | 3,756.00 |
| Sep 30, 2025 | 457.00 |
| Jun 30, 2025 | 1,810.00 |
| Mar 31, 2025 | 3,135.00 |
| Dec 31, 2024 | 4,432.00 |
| Sep 30, 2024 | 1,049.00 |
| Jun 30, 2024 | 4,154.00 |
| Mar 31, 2024 | 7,186.00 |
| Dec 31, 2023 | 10,145.00 |
| Sep 30, 2023 | 279.00 |
| Jun 30, 2023 | 1,948.00 |
| Mar 31, 2023 | 3,861.00 |
| Dec 31, 2022 | 3,635.00 |
| Sep 30, 2022 | 2,119.00 |
| Jun 30, 2022 | 627.00 |
| Mar 31, 2022 | 2,494.00 |
| Dec 31, 2021 | 4,470.00 |
| Jun 30, 2021 | 845.00 |
| Mar 31, 2021 | 2,099.00 |